On March 25, 2025 Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, reported that it will present updated clinical and translational results for its lead selective T cell activator, invikafusp alfa (STAR0602), in a clinical plenary oral presentation at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 26-30, 2025, in Chicago, Illinois (Press release, Marengo Therapeutics, MAR 25, 2025, View Source [SID1234651426]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Title: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1/2 trial of invikafusp alfa, a first-in-class TCR β chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors
Conference: AACR (Free AACR Whitepaper) Annual Meeting 2025
Abstract Number: CT205
Session Title: Clinical Trials Plenary: Biologics and T-cell Engagers
Session Date and Time: Tuesday, April 29, 2025, 10:15 AM – 12:15 PM
Presenter: Ryan J. Sullivan, M.D., (Massachusetts General Hospital, Boston, MA, USA)